Caxton Associates (New York)’s NeoGenomics NEO Stock Holding History

Caxton Associates (New York)’s Portfolio NEO Stock Details NEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-48,535	Closed	-$590K	–	686
2022 Q1	$590K	Buy	48,535 +42,627	+722%	+$897K	0.05%	204
2021 Q4	$202K	Buy	+5,908	New	+$231K	0.02%	490
2019 Q2	–	Sell	-33,516	Closed	-$686K	–	486
2019 Q1	$686K	Buy	+33,516	New	+$582K	0.1%	105

Other funds holding NEO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return

Caxton Associates (New York)'s NEO Position: Q2 2022 in Review

Caxton Associates (New York) sold out of NeoGenomics (NEO) in Q2 2022, closing a stake of 48,535 shares — an estimated $590K sold.

Caxton Associates (New York) first reported a position in NEO in Q1 2019 and held it in 3 quarters. The position peaked at $686K in Q1 2019. 239 funds tracked by Wall St. Rank hold NEO as of Q2 2022.

Caxton Associates (New York) reported no remaining NeoGenomics position as of Q2 2022 after selling out during the quarter.
Caxton Associates (New York) sold 48,535 NeoGenomics shares in Q2 2022, an estimated $590K.
Caxton Associates (New York) first reported a position in NeoGenomics in Q1 2019 and held it in 3 quarters.
Caxton Associates (New York)'s NeoGenomics position peaked at $686K in Q1 2019.
239 funds tracked by Wall St. Rank held NeoGenomics as of Q2 2022.

Based on Caxton Associates (New York)'s 13F filing for Q2 2022, filed 15 Aug 2022.